Antengene Corporation Limited (SEHK:6996), a China-based, commercial-stage global biopharmaceutical company focused on discovering, developing and commercialising first-in-class and/or best-in-class medicines for cancer, announced on Sunday that an abstract featuring the latest data from a Phase I/II study of the Claudin 18.2 antibody-drug conjugate (ADC), ATG-022, has been accepted for poster presentation at the 2025 European Society for Medical Oncology Annual Congress (ESMO 2025), taking place in October in Berlin, Germany.

ATG-022 is an ADC designed to target CLDN18.2, a member of the Claudin family of cell adhesion molecules. The US Food and Drug Administration (FDA) has awarded Orphan Drug Designations to ATG-022 for gastric and pancreatic cancers.

According to Antengene, data from the ongoing CLINCH study demonstrated that ATG-022 delivers robust efficacy across all levels of CLDN18.2 expression in gastric cancer patients, including those with high, low and ultra-low expression.